EUCTR2014-000506-35-GB进行中（未招募）1 期
Carfilzomib/Cyclophosphamide/Dexamethasone with maintenance carfilzomib in untreated transplant-eligible patients with symptomatic MM to evaluate the benefit of upfront ASCT - Cardamon trial
niversity College London0 个研究点目标入组 280 人开始时间: 2014年12月11日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 280
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Previously untreated patients with symptomatic MM (see appendix 2) eligible for stem cell transplantation, with the exception of the following treatments:
- •olocal radiotherapy to relieve bone pain and/or spinal cord compression
- •obisphosphonates
- •ocorticosteroids within the last 3 months. Within 14 days prior to study entry, the maximum permitted dose is 160mg (i.e. 4 days of Dexamethasone at 40mg, or equivalent), unless otherwise agreed by the TMG.
- •Suitable for high dose therapy and ASCT
- •Age = 18 years
- •Life expectancy = 3 months
- •Eastern Cooperative Oncology Group (ECOG) performance status 0–2), except:
- •oECOG >2 is permissible if resulting from complications related to myeloma (i.e. due to spinal cord compression). Please check with UCL CTC if unsure as to whether this exception may be applicable.
- •Measurable disease as defined by one of the following:
- •oSecretory myeloma:
- •Either monoclonal protein in the serum (=10 g/L)
- •Or monoclonal light chain in the urine (Bence Jones protein =200mg/24hours)
- •Or serum free light chain (SFLC, involved light chain =100mg/L provided the FLC ratio is abnormal)
- •oNon-secretory myeloma:
- •Either =30% clonal plasma cells in bone marrow (aspirate or trephine)
- •Or 10-30% clonal plasma cells in the marrow and >1 soft tissue or extra-osseous plasmacytoma = 2 cm that is measurable for response assessment by CT or MRI
- •Adequate hepatic function, with serum ALT = 3.5 times the upper limit of normal and serum direct bilirubin = 2 mg/dL (34 µmol/L) within 14 days prior to registration
- •Absolute neutrophil count (ANC) = 1.0 × 109/L within 14 days prior to registration and subject has not received any growth factor support within 7 days of testing. ANC=0.8x109/L allowed for patients with racial neutropenia.
- •Haemoglobin = 8 g/dL (80 g/L) within 14 days prior to registration (subjects may be receiving red blood cell (RBC) transfusions in accordance with institutional guidelines)
- •Platelet count = 75 × 109/L (= 50 × 109/L if myeloma involvement in the bone marrow is > 50%) within 14 days prior to registration and subject has not received any platelet transfusions within 7 days prior to testing
- •Creatinine clearance (CrCl) = 30 mL/minute within 14 days prior to registration, either measured or calculated using a standard formula (e.g. Cockcroft and Gault)
- •Written informed consent
- •Females of childbearing potential (FCBP) must agree to ongoing pregnancy testing and to practice contraception
- •Male subjects must agree to practice contraception
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 236
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 44
排除标准
- •Pregnant or breast-feeding females (lactating women may participate if breastfeeding ceases for the duration of trial treatment and until 12 months after last treatment)
- •Previous systemic chemotherapy for myeloma, with the exception of steroids, as detailed above (see section 6.3.1)
- •Any major surgery within 21 days prior to registration which in the investigator’s opinion would compromise trial treatment and/or the patient’s ability to comply with trial visits. Surgery to relieve spinal cord compression or for treatment of bone fractures is permitted
- •Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) 7 days prior to planned start of treatment, unless otherwise agreed by the TMG
- •Known human immunodeficiency virus (HIV) infection
- •Active hepatitis B or C infection (refer to appendix 4)
- •Unstable angina or myocardial infarction within 4 months prior to registration, NYHA Class III or IV heart failure, uncontrolled angina, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless subject has a pacemaker
- •Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to registration
- •Non-haematologic malignancy within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localised transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas
- •Significant neuropathy (Grades 3–4, or Grade 2 with pain) within 14 days prior to registration
- •Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilise carfilzomib)
- •Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary, cardiac or renal impairment
- •Patients with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to registration
- •Any other clinically significant medical disease or condition that, in the Investigator’s opinion, may interfere with protocol adherence or a subject’s ability to give informed consent
研究者
相似试验
进行中（未招募）
1 期
Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Multiple MyelomaMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000054086EUCTR2016-005008-24-ESFUNDACIÓN PETHEMA270
已完成
2 期
Bortezomib, cyclophosphamide plusd dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myelomaJPRN-UMIN000009765Kanagawa Cancer Center30
进行中（未招募）
1 期
Carfilzomib + Lenalidomide +Dexamethasone for BTK inhibitors relapsed-refractory or intolerant mantle cell lymphomasBTK inhibitors relapsed-refractory or intolerant mantle cell lymphomasMedDRA version: 20.0Level: PTClassification code 10061275Term: Mantle cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000540-25-ITFONDAZIONE ITALIANA LINFOMI ONLUS59
招募中
2 期
Carfilzomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma: A Randomized Phase 2 StudySmoldering multiple myeloma10035227NL-OMON53146HOVO25
进行中（未招募）
1 期
Carfilzomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma.Smoldering multiple myelomaMedDRA version: 26.1Level: LLTClassification code 10075894Term: Smoldering myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000555-10-NOHOVON Foundation81